<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cladribine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cladribine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cladribine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11331" href="/d/html/11331.html" rel="external">see "Cladribine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13164" href="/d/html/13164.html" rel="external">see "Cladribine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708674"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician (injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Cladribine should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression (injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy (oral tablet only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment with cladribine oral tablets may increase the risk of malignancy. Cladribine oral tablets are contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of cladribine oral tablets on an individual patient basis. Follow standard cancer screening guidelines in patients treated with cladribine oral tablets.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity (injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal toxicity (injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for hairy cell leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of teratogenicity (oral tablet only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cladribine oral tablets are contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with cladribine oral tablets in females of reproductive potential. Advise females and males of reproductive potential to use effective contraception during cladribine oral tablets dosing and for 6 months after the last dose in each treatment course. Stop cladribine oral tablets if the patient becomes pregnant.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52994085"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mavenclad (10 Tabs);</li>
<li>Mavenclad (4 Tabs);</li>
<li>Mavenclad (5 Tabs);</li>
<li>Mavenclad (6 Tabs);</li>
<li>Mavenclad (7 Tabs);</li>
<li>Mavenclad (8 Tabs);</li>
<li>Mavenclad (9 Tabs)</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866361"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mavenclad</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F152320"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Purine Analog);</li>
<li>
                        Immunosuppressant Agent</li></ul></div>
<div class="block doa drugH1Div" id="F152286"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections. For oncologic uses, assess risk for tumor lysis syndrome; consider antihyperuricemics and hydrate accordingly. Cladribine may be dosed in mg/kg or in mg/m<sup>2</sup>; use caution with dose calculations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute myeloid leukemia (newly diagnosed), induction (off-label use):</b> DAC regimen:<b> IV:</b> 5 mg/m<sup>2</sup> over 3 hours on days 1 to 5 (in combination with daunorubicin and cytarabine); a second induction cycle may be administered if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22508825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22508825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute myeloid leukemia (relapsed/refractory), induction (off-label use): </b>CLAG or CLAG-M regimen:<b> IV:</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days (in combination with cytarabine and filgrastim ± mitoxantrone); a second induction cycle may be administered if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10975390','lexi-content-ref-18076637','lexi-content-ref-12930315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10975390','lexi-content-ref-18076637','lexi-content-ref-12930315'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6809a202-6933-4fe2-a689-981abd6e2a63">Hairy cell leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.14 mg/kg/day over 2 hours for 5 days for 1 cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27903528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27903528'])">Ref</a></span>) <b>or</b> 0.1 mg/kg/day continuous infusion for 7 days for 1 cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12610190','lexi-content-ref-9731048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12610190','lexi-content-ref-9731048'])">Ref</a></span>) <b>or</b> 0.09 mg/kg/day continuous infusion for 7 days for 1 cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fresenius.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fresenius.1'])">Ref</a></span>) <b>or</b> 0.15 mg/kg/day over 2 hours on days 1 to 5 as a single course (in combination with concurrent or delayed rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109194'])">Ref</a></span>) <b>or</b> 5.6 <b>mg/m<sup>2</sup></b> over 2 hours once daily for 5 days as a single course, followed 28 days later by rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109194','lexi-content-ref-21821712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109194','lexi-content-ref-21821712'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b> (off-label route): 0.1 to 0.14 mg/kg/day for 5 days for 1 cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27903528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27903528'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b4f1f5e-9acc-4b4a-b4a9-3ccf159040d1">Mantle cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma (off-label use): IV:</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 weeks for 2 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18470909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18470909'])">Ref</a></span>) <b>or</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 to 5 weeks for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10076731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10076731'])">Ref</a></span>) <b>or</b> 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 4 weeks for 2 to 6 cycles (in combination with rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18470909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18470909'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Lymphocytes must be within normal limits before initiating first treatment course and ≥800 cells/mm<sup>3</sup> before initiating the second treatment course. If needed, the second treatment course can be delayed up to 6 months to allow lymphocytes to recover to ≥800 cells/mm<sup>3</sup>. If lymphocytes &lt;800 cells/mm<sup>3</sup> after 6-month delay, do not continue cladribine. Screen for HIV, tuberculosis, and hepatitis B and C status prior to each treatment course. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>). Initiating oral cladribine during concomitant treatment with immunosuppressive or myelosuppressive therapies is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 3.5 mg/kg over 2-year treatment course, administered as 1.75 mg/kg in each year. Divide the 1.75 mg/kg dose over 2 cycles, each cycle lasting 4 to 5 consecutive days; do not administer more than 20 mg/day. In the first-year treatment course, initiate the first cycle at any time; administer the second cycle 23 to 27 days after the last dose of the first cycle. In the second-year treatment course, initiate the first cycle ≥43 weeks after the last dose of the first year's second cycle. Administer the second cycle 23 to 27 days after the last dose of the second year's first cycle. Following 2 years of treatment, do not administer oral cladribine during the next 2 years. Refer to manufacturer's labeling for additional dosing details, including dosing tables.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses: </i> If a dose is not administered on a scheduled day, administer the missed dose on the following day and extend the number of days in that treatment cycle. If 2 consecutive doses are missed, extended the treatment cycle by 2 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09389367-6f75-4aaa-a400-92821738e568">T-cell large granular lymphocytic leukemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell large granular lymphocytic leukemia, refractory (off-label use; based on limited data): IV:</b> 0.1 mg/kg/day continuous infusion for 7 days for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9092691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9092691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.1 mg/kg/day continuous infusion for 7 days every 4 weeks for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7989946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7989946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 0.1 mg/kg/day for 5 consecutive days every month for 4 cycles (in combination with rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20368573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20368573'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991265"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR-based dosing:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≤50 mL/minute: Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Creatinine clearance-based dosing:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute: Administer 75% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 50% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous renal replacement therapy (CRRT): Administer 50% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;60 mL/minute: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988423"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): Dosage adjustment is not likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (Child-Pugh class B or C): Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment (Child-Pugh classes B and C): Use is not recommended (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F20339799"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">Hematology/Oncology uses: <i>ASCO guidelines</i>
<i> for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F58302529"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Decreased lymphocytes: Consider interrupting or delaying oral cladribine treatment in patients with lymphocyte counts &lt;500/mm<sup>3</sup> and signs or symptoms of infections, including herpes infections. If lymphocyte counts &lt;200 cells/mm<sup>3</sup>, withhold cladribine and administer anti-herpes prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatotoxicity: If unexplained liver enzyme elevations or symptoms of liver dysfunction develop, including abdominal pain, anorexia, dark urine, fatigue, jaundice, or unexplained nausea or vomiting, interrupt or discontinue cladribine treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity (suspected): Discontinue cladribine.</p>
<p style="text-indent:-2em;margin-left:4em;">Progressive multifocal leukoencephalopathy (PML): Withhold cladribine and perform diagnostic evaluation at the first sign or symptom suggestive of PML.</p></div>
<div class="block doe drugH1Div" id="F152287"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F152303"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13164" href="/d/html/13164.html" rel="external">see "Cladribine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia:</b> Limited data available: Infants, Children, and Adolescents: IV: 8.9 mg/m<sup>2</sup>/day continuous infusion for 5 days for 1 or 2 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11387351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11387351'])">Ref</a></span>) or 9 mg/m<sup>2</sup>/day over 30 minutes for 5 days for 1 course (in combination with cytarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12377965','lexi-content-ref-19242495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12377965','lexi-content-ref-19242495'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9438acbe-e23c-4fe9-baa0-396aaeb88ad9">Langerhans cell histiocytosis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Langerhans cell histiocytosis, refractory:</b> Limited data available: Infants, Children, and Adolescents: IV: 5 mg/m<sup>2</sup>/day over 2 hours for 5 days every 21 days for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19731321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19731321'])">Ref</a></span>); has also been administered as a continuous IV infusion: 5 mg/m<sup>2</sup>/day over 24 hours for 3 days; if tolerated, dose increased to 6.5 mg/m<sup>2</sup>/day over 24 hours for 3 days for subsequent courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15170896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15170896'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51089927"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution. The following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 30% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 30% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): Administer 50% of dose.</p></div>
<div class="block dohp drugH1Div" id="F51108495"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (due to inadequate data); use with caution.</p></div>
<div class="block adr drugH1Div" id="F152257"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Bone marrow depression (34%, may be delayed onset), febrile neutropenia (47%), severe anemia (37%), severe neutropenia (70%), thrombocytopenia (12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Bacterial infection (12%), infection (28%; serious infection: 6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (69%; high fever: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%: Infection: Fungal infection (6%), herpes zoster infection (4%), viral infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Edema, peripheral edema, phlebitis, tachycardia</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Ecchymosis, hyperhidrosis, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, flatulence, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Bruise, decreased CD-4 cell count (nadir occurred 4 to 6 months following treatment and may continue to be depressed &gt;15 months), petechia, purpuric disease</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Bacteremia, localized infection, septicemia</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Bleeding at injection site, injection site reaction, localized edema</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety, chills, dizziness, fatigue, headache, insomnia, malaise, myasthenia, pain, severe neurotoxicity</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, myalgia</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Abnormal breath sounds, cough, dyspnea, rales</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis, viral skin infection</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Progressive multifocal leukoencephalopathy</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Pneumonia, respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Decreased hemoglobin (26%), decreased platelet count (11%), lymphocytopenia (24% to 87%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction (11%; severe hypersensitivity reaction: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Infection (49%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (25%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Upper respiratory tract infection (38%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypertension (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (10%), oral herpes simplex infection (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Neutropenia (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Herpes virus infection (6%), herpes zoster infection (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Depression (5%), insomnia (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (≤7%), arthritis (≤7%), back pain (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Bronchitis (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Cardiac failure, myocarditis</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatic injury</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Seizure (tonic clonic), status epilepticus</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Tuberculosis</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Malignant melanoma, malignant neoplasm, malignant neoplasm of ovary, pancreatic adenocarcinoma</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Coccidioidomycosis, fungal infection</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Pyelonephritis</p></div>
<div class="block coi drugH1Div" id="F152269"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cladribine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral tablet: Current malignancy; pregnancy; individuals of reproductive potential who do not plan to use effective contraception during therapy and for 6 months after the last dose in each treatment course; HIV infection; active chronic infections (eg, hepatitis or tuberculosis); breastfeeding (during treatment and for 10 days after last dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral tablet [Canadian product]: Additional contraindications (not in US labeling): Increased risk of opportunistic infections (including those immunocompromised due to therapy [immunosuppressive or immunomodulating, antineoplastic or myelosuppressive therapies; total lymphoid irradiation; bone marrow transplantation] or disease [immunodeficiency syndrome]); history of progressive multifocal leukoencephalopathy; moderate or severe renal impairment (CrCL &lt;60 mL/minute).</p></div>
<div class="block war drugH1Div" id="F152254"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Dose-dependent myelosuppression (neutropenia, anemia, and thrombocytopenia) is common with cladribine injection and generally reversible. Lymphopenia has also been reported in patients receiving oral tablets for multiple sclerosis (MS). Use with caution in patients with preexisting hematologic or immunologic abnormalities and patients receiving other drugs that affect the hematologic profile concurrently or prior to treatment with cladribine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiotoxicity: Cardiotoxicity, including life-threatening acute cardiac failure with myocarditis, has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fever: Treatment is associated with fever (≥100°F), with or without neutropenia, and is observed more commonly in the first month of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Graft-versus-host disease: Graft-versus-host disease (GVHD) has been reported rarely in cladribine treated patients following transfusions of nonirradiated blood. Consult with a hematologist; irradiation of cellular blood components prior to transfusion is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious liver injury or liver injury leading to treatment discontinuation has been reported within a few weeks to several months after initiation of cladribine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and potentially fatal infections (bacterial, viral, and fungal) have been reported. Due to neutropenia and T-cell depletion, risk versus benefit of treatment should be evaluated in patients with active infections. If active infection is present, manage appropriately prior to administering cladribine (Grever 2017). For the treatment of MS, screen for HIV, tuberculosis, and hepatitis B and C status prior to each treatment course. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]). Initiating oral cladribine during concomitant treatment with immunosuppressive or myelosuppressive therapies is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Treatment with cladribine oral tablets may increase the risk of malignancy. After the completion of 2 courses of treatment, do not administer cladribine oral tablets for 2 years. Cladribine oral tablets are contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits versus risks of cladribine oral tablets based on individual patient factors. Follow standard cancer screening guidelines in patients treated with cladribine oral tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Serious, dose-related neurologic toxicity (including irreversible paraparesis and quadriparesis) has been reported with continuous IV infusions of higher doses (4 to 9 times the approved dose); may also occur at approved doses (rare). Neurotoxicity may be delayed and may present as progressive, irreversible motor weakness of the upper and/or lower extremities; diagnostics with electromyography and nerve conduction studies were consistent with demyelinating disease. Neurotoxicity after high-dose administration was first noted 35 to 84 days after therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Cases of progressive multifocal leukoencephalopathy (PML) due to the John Cunningham (JC) virus have been reported in patients receiving parenteral cladribine for oncologic indications. Symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. MRI findings may be apparent before patients are symptomatic. Monitoring with brain MRI for signs that may be consistent with PML may be beneficial and allow for an early diagnosis of PML.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Acute nephrotoxicity (eg, acidosis, anuria, increased serum creatinine), possibly requiring dialysis, has been reported with high doses (4 to 9 times the approved dose), particularly when administered with other nephrotoxic agents. Per the manufacturer, nephrotoxicity has not occurred when used at the dose approved for hairy cell leukemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: With high tumor burden, tumor lysis syndrome and subsequent hyperuricemia may occur (rare).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Injection: Weekly (7-day) infusion preparation recommends further dilution with bacteriostatic normal saline which contains benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: When used in the oncology setting, administration of live-attenuated or live vaccines is not recommended during treatment with cladribine (may increase the risk of infection due to immunosuppression). When using for the treatment of MS, complete necessary immunizations at least 4 to 6 weeks prior to initiating cladribine. Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued cladribine; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]). Provide varicella zoster virus (VZV) vaccination prior to initiation of therapy in VZV antibody–negative patients. In antibody-positive patients, vaccination with zoster vaccine (recombinant) is recommended any time prior to or during the course of treatment; may also administer if lymphocyte counts are ≤500 cells/mm<sup>3</sup>
<sub>.</sub></p></div>
<div class="block foc drugH1Div" id="F152263"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (10 Tabs): 10 mg [five packs containing 2 tablets ea] (10 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (4 Tabs): 10 mg [four packs containing 1 tablet] (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (5 Tabs): 10 mg [five packs containing 1 tablet] (5 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (6 Tabs): 10 mg [one pack containing 2 tablets; four packs containing 1 tablet] (6 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (7 Tabs): 10 mg [two packs containing 2 tablets ea; three packs containing 1 tablet ea] (7 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (8 Tabs): 10 mg [three packs containing 2 tablets ea; two packs containing 1 tablet ea] (8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad (9 Tabs): 10 mg [four packs containing 2 tablets ea; one pack containing 1 tablet] (9 ea)</p></div>
<div class="block geq drugH1Div" id="F152250"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323071"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cladribine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $42.00 - $52.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (10 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (4 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (5 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (6 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (7 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (8 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Mavenclad (9 Tabs) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $11,791.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866362"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (10 mL, 20 mL); 10 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mavenclad: 10 mg (1 ea, 4 ea, 5 ea, 6 ea, 7 ea, 8 ea)</p></div>
<div class="block adm drugH1Div" id="F152266"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Usually administered as a continuous infusion or over 2 hours; infusions over 3 hours have also been reported; refer to specific reference for infusion rate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ</b> (off-label route)<b>:</b> May also be administered SUBQ (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27903528','lexi-content-ref-20368573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27903528','lexi-content-ref-20368573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with water (with or without food); swallow whole immediately after removing from packaging; do not chew. Patients should use dry hands for handling and avoid prolonged contact with skin; wash hands and any surface that came in contact with the tablet thoroughly afterwards. Separate administration from any other oral medication by 3 hours. Refer to manufacturer's labeling for additional administration detail.</p></div>
<div class="block admp drugH1Div" id="F52612430"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Further dilute prior to use, may be administered over 24 hours as a continuous infusion, or as an intermittent infusion over 30 minutes or 2 hours; dependent upon indication and/or protocol.</p></div>
<div class="block hazard drugH1Div" id="F49130932"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F52959760"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Mavenclad: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022561s006lbl.pdf%23page%3D29&amp;token=g%2FG4y4boQR3jR%2B2qwsmZmZQOm%2BXh716aoX8fVyO2nqssgXKUlyB0o30YMTcJn4bXwVqALgecnVH1c7vWbSnn10ojHqxPp9FxsCCE2OZ7QU74sNd%2FrmCYtyqhnrTeMICv&amp;TOPIC_ID=9272" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022561s006lbl.pdf#page=29</a></p></div>
<div class="block use drugH1Div" id="F152264"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia (injection only)</b>: Treatment of active hairy cell leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing (oral tablet only):</b> Treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting (RRMS) and active secondary progressive disease in adults who have had inadequate response or are intolerant to other therapies for multiple sclerosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not recommended for patients with clinically isolated syndrome.</p></div>
<div class="block off-label drugH1Div" id="F25722026"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute myeloid leukemia; Mantle cell lymphoma; T-cell large granular lymphocytic leukemia (refractory); Waldenström macroglobulinemia</p></div>
<div class="block mst drugH1Div" id="F152326"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cladribine may be confused with clevidipine, clofarabine, cytarabine, fludarabine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leustatin may be confused with lovastatin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299054"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6219339"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents that Undergo Intracellular Phosphorylation: May diminish the therapeutic effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Inducers: May decrease the serum concentration of Cladribine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Inhibitors: May increase the serum concentration of Cladribine. Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins: May increase the serum concentration of Cladribine. Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Beta): Cladribine may enhance the adverse/toxic effect of Interferons (Beta). Specifically, the risk for lymphopenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Cladribine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: Cladribine may enhance the myelosuppressive effect of Myelosuppressive Agents. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Cladribine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Cladribine may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Cladribine may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Cladribine may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: May increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Recombinant): Cladribine may diminish the therapeutic effect of Zoster Vaccine (Recombinant).  Management: Vaccination with recombinant zoster vaccine is permitted for seropositive patients. Seronegative patients should be vaccinated prior to cladribine therapy. Consider revaccination 3 months after therapy for patients vaccinated during cladribine therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49296631"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; exclude pregnancy prior to each treatment course in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 6 months after the last dose of cladribine, regardless of the route of administration/indication for treatment. Patients with partners who could become pregnant should also use effective contraception during therapy and for 6 months after the last cladribine dose. Use of oral cladribine is contraindicated in patients of reproductive potential who do not plan to use effective contraception during therapy and for 6 months after the last dose.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis are stopped prior to a planned pregnancy except in patients at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]). Consider use of agents other than cladribine for patients at high risk of disease reactivation who are planning a pregnancy. Delaying pregnancy is recommended for patients with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F3016299"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to cladribine is expected to cause fetal harm. Discontinue cladribine if pregnancy occurs during treatment; use of oral cladribine during pregnancy is contraindicated.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data related to the use of cladribine for the treatment of hairy cell leukemia (Daver 2013) or multiple sclerosis (Dost-Kovalsky 2023; Giovannoni 2020) during pregnancy are limited.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis are not initiated during pregnancy, except in patients at high risk of multiple sclerosis activity (AAN [Rae-Grant 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to cladribine for the treatment of patients with multiple sclerosis is ongoing. Health care providers are encouraged to enroll patients exposed to cladribine during pregnancy or within 6 months prior to pregnancy in the EMD Serono’s Adverse Event reporting line (800-283-8088 ext. 5563); patients may also enroll themselves.</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F3016301"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cladribine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of cladribine in breast milk are available from a patient treated for relapsing-remitting multiple sclerosis after experiencing a relapse. Four months postpartum she was treated with cladribine 20 mg once daily for 4 days, then 10 mg on day 5. Five weeks later she was treated with cladribine 20 mg once daily for 3 days, then 10 mg daily for 2 days. Breast milk was sampled over 24 hours during the second treatment. One hour following a 20 mg dose on day 3, breast milk concentrations of cladribine were 281.2 ng/mL and then decreased rapidly. At 48, 72, and 96 hours after the last dose, cladribine breast milk concentrations were below the limit of quantification (1.5 ng/mL). Using the average breast milk concentration, authors of the study calculated the estimated daily infant dose via breast milk to be 0.0066 mg/kg/day, providing a relative infant dose (RID) of 3.06% compared to a weight-adjusted maternal dose of cladribine 20 mg. Breastfeeding was suspended during treatment (Datta 2021). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Use of the oral tablet is contraindicated in lactating patients during treatment and for 10 days after the last cladribine dose. Due to the potential for serious adverse reactions in the breastfed infant, manufacturers of cladribine injection recommend discontinuing cladribine or discontinuing breastfeeding, considering the importance of treatment to the mother. Some sources recommended withholding breastfeeding for at least 48 hours after the last cladribine dose, longer in patients with impaired renal function (Almas 2016).</p></div>
<div class="block mop drugH1Div" id="F152261"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">IV: CBC with differential (at baseline, during, and after treatment; particularly during the first 4 to 8 weeks post-treatment), renal and hepatic function; bone marrow biopsy (after CBC has normalized, to confirm treatment response). Monitor for fever; monitor for signs/symptoms of neurotoxicity, infection, hepatotoxicity, progressive multifocal leukoencephalopathy (PML), and tumor lysis syndrome. Assess risk for opportunistic infections (eg, <i>pneumocystis jirovecii pneumonia</i>, herpes virus infection).</p>
<p style="text-indent:-2em;margin-left:4em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral tablet: CBC including lymphocyte count (before each treatment course, 2 and 6 months after the start of each yearly course [if 2-month lymphocyte &lt;200 cells/mm<sup>3</sup>, monitor monthly until month 6], and periodically during and after treatment); liver function tests (serum aminotransferase, alkaline phosphatase, and total bilirubin levels) (prior to each treatment course and as clinically appropriate). Evaluate HIV, tuberculosis, hepatitis B (HBV) and hepatitis C (HCV) status (prior to each treatment course); evaluate varicella zoster virus (VZV) antibody status (prior to treatment initiation). Verify pregnancy status (prior to each treatment course in patients who could become pregnant). MRI (at baseline [within 3 months] prior to first treatment course). Monitor for signs or symptoms of progressive multifocal leukoencephalopathy (if suspected, perform a diagnostic evaluation and obtain brain MRI scan); follow standard guidelines for cancer screening; monitor for signs or symptoms of acute infection.</p></div>
<div class="block pha drugH1Div" id="F152253"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cladribine is a purine nucleoside analogue; it is a prodrug which is activated by phosphorylation and converted into the active moiety, Cd-ATP. This active form incorporates into DNA to result in the breakage of DNA strand and shutdown of DNA synthesis and repair. This also results in a depletion of nicotinamide adenine dinucleotide and adenosine triphosphate (ATP). Cladribine is cell-cycle nonspecific. The mechanism of cladribine in treating multiple sclerosis (MS) is unknown, but may involve cytotoxic effects on B and T lymphocytes that result from the shutdown of DNA synthesis, leading to a depletion of lymphocytes.</p></div>
<div class="block phk drugH1Div" id="F152268"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid; delayed with food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 8 months to 18 years: 12.7 ± 8.5 L/kg; penetrates CSF (CSF concentrations are ~18% of plasma concentration) (Kearns 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 480 to 490 L or ~9 L/kg; penetrates CSF (CSF concentrations are ~25% of plasma concentrations)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~20%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Prodrug; activated via phosphorylation to active metabolite, Cd-ATP; negligible hepatic metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral tablet: ~40%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 8 months to 18 years: IV: 19.7 ± 3.4 hours (Kearns 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: After a 2-hour infusion (with normal renal function): 5.4 hours; Oral: ~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: Median 0.5 hour (range 0.5 to 1.5 hours) (fasting); 1.5 hours (range 1 to 3 hours) (with high-fat meal)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (18% to 28.5%)</p></div>
<div class="block phksp drugH1Div" id="F52994160"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (CrCl 60 to 90 mL/minute): 18% decrease in total clearance; 25% increase in cladribine exposure</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or serious impairment: Limited clinical experience.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038562"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cladrim | Mavenclad</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dricaleu | Intocel | Leustat | Mavenclad | Nadrib</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad | Movectro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cladribine Dci | Leustatine | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Leustat | Mavenclad</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Leustat | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cladrim</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Leustatin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Leustatin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Biodribin | Leikladin | Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cladrim | Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Leustatin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biodribin | Leustatin | Mavenclad | Ocladra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mavenclad</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Leicladin | Mavenclad | Movectro | Vero Cladribine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Leustatin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Litak | Mavenclad</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Leustatin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Litak</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ocladra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Mavenclad</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Movenclad</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Leustatin | Litak | Mavenclad</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi: 10.1155/2016/6527458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291085">
<a name="16291085"></a>Bernard F, Thomas C, Bertrand Y, et al. Multi-Centre Pilot Study of 2-Chlorodeoxyadenosine and Cytosine Arabinoside Combined Chemotherapy in Refractory Langerhans Cell Histiocytosis With Haematological Dysfunction. <i>Eur J Cancer</i>. 2005;41(17):2682-2689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/16291085/pubmed" id="16291085" target="_blank">16291085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109194">
<a name="32109194"></a>Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. <i>J Clin Oncol.</i> 2020;38(14):1527-1538. doi:10.1200/JCO.19.02250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/32109194/pubmed" id="32109194" target="_blank">32109194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27301277">
<a name="27301277"></a>Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. <i>Br J Haematol</i>. 2016;174(5):760-766. doi:10.1111/bjh.14129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/27301277/pubmed" id="27301277" target="_blank">27301277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Cladribine injection [prescribing information]. Rockford, IL: Mylan Institutional LLC; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Cladribine injection [prescribing information]. Lake Surich, IL: Fresenius Kabi; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hisun.1">
<a name="Hisun.1"></a>Cladribine injection, USP [prescribing information]. Bridgewater, NJ: Hisun Pharmaceuticals USA Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.2">
<a name="Fresenius.2"></a>Cladribine injection [product monograph]. Richmond Hill, Ontario, Canada: Fresenius Kabi Canada Ltd; June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12377965">
<a name="12377965"></a>Crews KR, Gandhi V, Srivastava DK, et al. Interim Comparison of a Continuous Infusion versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. <i>J Clin Oncol</i>. 2002;20(20):4217-4224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12377965/pubmed" id="12377965" target="_blank">12377965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32507055">
<a name="32507055"></a>Datta P, Ciplea AI, Rewers-Felkins K, et al. Cladribine transfer into human milk: a case report. <i>Mult Scler</i>. 2021;27(5):799-801. doi:10.1177/1352458520912173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/32507055/pubmed" id="32507055" target="_blank">32507055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22981963">
<a name="22981963"></a>Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. <i>Clin Lymphoma Myeloma Leuk</i>. 2013;13(1):86-89. doi:10.1016/j.clml.2012.06.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/22981963/pubmed" id="22981963" target="_blank">22981963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7989946">
<a name="7989946"></a>Dimopoulos MA, Kantarjian H, Weber D, et al. Primary Therapy of Waldenström's Macroglobulinemia With 2-Chlorodeoxyadenosine. <i>J Clin Oncol</i>. 1994;12(12):2694-2698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/7989946/pubmed" id="7989946" target="_blank">7989946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36278327">
<a name="36278327"></a>Dost-Kovalsky K, Thiel S, Ciplea AI, Gold R, Hellwig K. Cladribine and pregnancy in women with multiple sclerosis: the first cohort study. <i>Mult Scler</i>. 2023;29(3):461-465. doi:10.1177/13524585221131486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/36278327/pubmed" id="36278327" target="_blank">36278327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9092691">
<a name="9092691"></a>Edelman MJ, O’Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. <i>Am J Hematol.</i> 1997;54(4):329-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9092691/pubmed" id="9092691" target="_blank">9092691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32447743">
<a name="32447743"></a>Giovannoni G, Galazka A, Schick R, et al. Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. <i>Drug Saf</i>. 2020;43(7):635-643. doi:10.1007/s40264-020-00948-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/32447743/pubmed" id="32447743" target="_blank">32447743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12610190">
<a name="12610190"></a>Goodman GR, Burian C, Koziol JA., et al. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine. <i>J Clin Oncol</i>. 2003;21(5):891-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12610190/pubmed" id="12610190" target="_blank">12610190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27903528">
<a name="27903528"></a>Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i>. 2017;129(5):553-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/27903528/pubmed" id="27903528" target="_blank">27903528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22508825">
<a name="22508825"></a>Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. <i>J Clin Oncol</i>. 2012;30(20):2441-2448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/22508825/pubmed" id="22508825" target="_blank">22508825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18470909">
<a name="18470909"></a>Inwards DJ, Fishkin PA, Hillman DW, et al. Long-Term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group. <i>Cancer</i>. 2008;113(1):108-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/18470909/pubmed" id="18470909" target="_blank">18470909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7906999">
<a name="7906999"></a>Kearns CM, Biakley RL, Santane VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. <i>Cancer Res</i>. 1994;54(5):1235-1239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/7906999/pubmed" id="7906999" target="_blank">7906999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11387351">
<a name="11387351"></a>Krance RA, Hurwitz CA, Head DR, et al. Experience With 2-Chlorodeoxyadenosine in Previously Untreated Children With Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Diseases. <i>J Clin Oncol.</i> 2001;19(11):2804-2811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11387351/pubmed" id="11387351" target="_blank">11387351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8558197">
<a name="8558197"></a>Larson RA, et al. Dose Escalation Trial of Cladribine Using 5 Daily I.V. Infusions in Patients with Advanced Hematologic Malignancies. <i>J Clin Oncol</i>. 1996;14(1):188-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/8558197/pubmed" id="8558197" target="_blank">8558197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20368573">
<a name="20368573"></a>Laszlo D, Andreola G, Rigacci L, et al. Rituximab and Subcutaneous 2-Chloro-2'-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>J Clin Oncol</i>. 2010;28(13):2233-2238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20368573/pubmed" id="20368573" target="_blank">20368573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9068927">
<a name="9068927"></a>Liliemark J. The Clinical Pharmacokinetics of Cladribine. <i>Clin Pharmacokinet</i>. 1997;32:120-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9068927/pubmed" id="9068927" target="_blank">9068927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMD.1">
<a name="EMD.1"></a>Mavenclad (cladribine) [prescribing information]. Rockland, MA: EMD Serono Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMD.2">
<a name="EMD.2"></a>Mavenclad (cladribine) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi:10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in <i>Neurology</i>. 2019;92(2):112]. <i>Neurology</i>. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21821712">
<a name="21821712"></a>Ravandi F, O'Brien S, Jorgensen J, et al. Phase 2 Study of Cladribine Followed by Rituximab in Patients With Hairy Cell Leukemia. <i>Blood</i>. 2011;118(14):3818-3823. doi:10.1182/blood-2011-04-351502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/21821712/pubmed" id="21821712" target="_blank">21821712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11426528">
<a name="11426528"></a>Robak T. Cladribine in the Treatment of Chronic Lymphocytic Leukemia. <i>Leuk Lymphoma.</i> 2001;40(5-6):551-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11426528/pubmed" id="11426528" target="_blank">11426528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11891804">
<a name="11891804"></a>Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of Children With Langerhans Cell Histiocytosis With 2-Chlorodeoxyadenosine. <i>Am J Hematol</i>. 2002;69(3):179-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/11891804/pubmed" id="11891804" target="_blank">11891804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20212251">
<a name="20212251"></a>Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide as First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). <i>J Clin Oncol</i>. 2010;28(11):1863-1869.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20212251/pubmed" id="20212251" target="_blank">20212251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10975390">
<a name="10975390"></a>Robak T, Wrzesien-Kus A, Lech-Marańda E, et al. Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Leuk Lymphoma</i>. 2000;39(1-2):121-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/10975390/pubmed" id="10975390" target="_blank">10975390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19242495">
<a name="19242495"></a>Rubnitz JE, Crews KR, Pounds S, et al. Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St Jude AML97 Trial. <i>Leukemia</i>. 2009;23(8):1410-1416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/19242495/pubmed" id="19242495" target="_blank">19242495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10076731">
<a name="10076731"></a>Rummel MJ, Chow KU, Jäger E. Treatment of Mantle Cell Lymphomas With Intermittent Two-Hour Infusion of Cladribine as First-Line Therapy or in First Relapse. <i>Ann Oncol</i>. 1999;10(1):115-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/10076731/pubmed" id="10076731" target="_blank">10076731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9731048">
<a name="9731048"></a>Saven A, Burian C, Koziol JA, et al. Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment. <i>Blood</i>. 1998;92(6):1918-1926.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9731048/pubmed" id="9731048" target="_blank">9731048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20634380">
<a name="20634380"></a>Sigal DS, Miller HJ, Schram ED, et al. Beyond Hairy Cell: The Activity of Cladribine in Other Hematologic Malignancies. <i>Blood</i>. 2010;116(16):2884-2896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20634380/pubmed" id="20634380" target="_blank">20634380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20056789">
<a name="20056789"></a>Sigal DS, Sharpe R, Burian C, et al. Very Long-Term Eradication of Minimal Residual Disease in Patients With Hairy Cell Leukemia After a Single Course of Cladribine. <i>Blood</i>. 2010;115(10):1893-1896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/20056789/pubmed" id="20056789" target="_blank">20056789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15170896">
<a name="15170896"></a>Stine KC, Saylors RL, Saccente S, et al. Efficacy of Continuous Infusion 2-CDA (Cladribine) in Pediatric Patients With Langerhans Cell Histiocytosis. <i>Pediatr Blood Cancer</i>. 2004;43(1):81-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/15170896/pubmed" id="15170896" target="_blank">15170896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9251735">
<a name="9251735"></a>Stine KC, Saylors RL, Williams LL, et al. 2-Chlorodeoxyadenosine (2-CDA) for the Treatment of Refractory or Recurrent Langerhans Cell Histiocytosis (LCH) in Pediatric Patients. <i>Med Pediatr Oncol</i>. 1997;29:288-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/9251735/pubmed" id="9251735" target="_blank">9251735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19731321">
<a name="19731321"></a>Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society. <i>Pediatr Blood Cancer</i>. 2009;53(7):1271-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/19731321/pubmed" id="19731321" target="_blank">19731321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18076637">
<a name="18076637"></a>Wierzbowska A, Robak T, Pluta A, et al. Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group. <i>Eur J Haematol</i>. 2008;80(2):115-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/18076637/pubmed" id="18076637" target="_blank">18076637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12930315">
<a name="12930315"></a>Wrzesien-Kus A, Robak T, Lech-Marańda E, et al. A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia – a Report of the Polish Adult Leukemia Group (PALG). <i>Eur J Haematol</i>. 2003;71(3):155–162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cladribine-drug-information/abstract-text/12930315/pubmed" id="12930315" target="_blank">12930315</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9272 Version 329.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
